Nov. 20 (Bloomberg) — Amgen Inc. ’s decision to suspend a clinical trial of its experimental cancer drug motesanib because of higher deaths among patients sets back the company’s efforts to expand in the market for oncology treatments.
Continued here:
Amgen Drug for Lung Cancer Suspended After Deaths (Update2) (Bloomberg)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.